James L. Bierman
Known title: DirectorCIK: 0001189534
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
Transaction History
| THC | ▼ Sell | Open Market | 5,000 | $1.2M | 7/27/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 50,913 | $185K | 6/10/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 28,609 | $185K | 6/18/2025 | View on chart |
| THC | ▼ Sell | Open Market | 4,613 | $784K | 5/29/2025 | View on chart |
| THC | ▼ Sell | Open Market | 1,551 | $257K | 5/27/2025 | View on chart |
| THC | ▼ Sell | Open Market | 8,836 | $1.4M | 5/23/2025 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| THC | ▼ Sell | Open Market | 5,000 | $800K | 5/23/2025 | View on chart |
| MDXG | ▲ Buy | Grant | 23,190 | $168K | 6/5/2024 | View on chart |
| MDXG | ▲ Buy | Grant | 35,354 | $175K | 6/13/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| MDXG | ▲ Buy | Grant | 44,191 | $175K | 6/7/2022 | View on chart |
| THC | ▲ Buy | Grant | 3,836 | $0 | 5/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.